Figus Michele, Posarelli Chiara, Albert Timothy G, Talarico Rosaria, Nardi Marco
Department of Surgical, Medical, Molecular Pathology and Department of Emergency, University of Pisa, 56100 Pisa, Italy.
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56100 Pisa, Italy.
Biomed Res Int. 2015;2015:120519. doi: 10.1155/2015/120519. Epub 2015 Oct 19.
Adamantiades-Behçet's disease is a multisystemic vasculitis with multiorgan involvement. Ocular disorders occur often in this syndrome typically in the form of a relapsing-remitting panuveitis and vasculitis and can lead to blindness as one of its most disabling complications if left untreated. There are known risk factors related with the worst visual prognosis, which require early and intensive treatment in order to obtain a rapid suppression of inflammation and to prevent future relapses. The management strategy to avoid vision loss and blindness currently involves the use of local and systemic drugs including steroids and immunosuppressive and biologic agents. This review aims to demonstrate how the introduction and the use of biologic agents improves the visual outcome of patients with Adamantiades-Behçet's disease.
白塞病是一种累及多系统、多器官的血管炎。眼部疾病在该综合征中较为常见,通常表现为复发缓解型全葡萄膜炎和血管炎,如果不进行治疗,失明是其最严重的致残性并发症之一。已知存在与最差视力预后相关的危险因素,这就需要早期强化治疗,以便迅速抑制炎症并预防未来复发。目前避免视力丧失和失明的管理策略包括使用局部和全身药物,如类固醇、免疫抑制剂和生物制剂。本综述旨在说明生物制剂的引入和使用如何改善白塞病患者的视力预后。